HANGZHOU, China, Dec. 20, 2023 /PRNewswire/ -- Recently, a CAR-macrophage therapy product (CAR-M) SY001 from CellOrigin Biotechnology (Hangzhou) Co., Ltd. was dosed to the first patient in a ...

Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

CellOrigin Biotech holds the domestic and global patents for iPSC-derived CAR-Macrophage, and the engineering for polarization.

Summary Macrophages are white blood cells that engulf and digest cellular debris, foreign substances, microbes, and cancer cells. Recently, scientists are exploring the method to make macrophage ...

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

HANGZHOU, China, Dec. 20, 2023 /PRNewswire/ -- Recently, a CAR-macrophage therapy product (CAR-M) SY001 from CellOrigin Biotechnology (Hangzhou) Co., Ltd. was dosed to the first patient in a ...